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Abstract
Introduction: The monoclonal anti-vascular endothelial growth factor antibody bevacizumab is increasingly used
in the treatment of several malignant tumors. The usual side effects of this drug are hypertension and proteinuria.
Paclitaxel is widely used in the treatment of breast cancer and head and neck carcinomas. Neither of these two
drugs typically causes skin disorders. Paclitaxel-related cutaneous lupus erythematosus has been described before,
but in earlier cases patients had a history of autoimmune disease.
Case presentation: We report a case of a 65-year-old Caucasian woman who presented with cutaneous lupus
erythematosus after receiving paclitaxel-bevacizumab combination treatment as first-line therapy for metastatic
breast cancer. Her cutaneous symptoms and increased serum anti-SSA and anti-SSB antibodies disappeared shortly
after the discontinuation of therapy.
Conclusion: We conclude that cutaneous lupus erythematosus can also be seen in patients without earlier
anamnesis of autoimmune disorders and that, furthermore, bevacizumab might cause atypical cutaneous side
effects.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
disease characterized by the presence of autoantibodies
to the nuclear and cytoplasmic antigens in conjunction
with several clinical manifestations [1]. Cutaneous lupus
lesions typically occur in light-exposed areas and can be
triggered by sunlight exposure [1]. Drug-induced lupus
erythematosus (DILE) is a syndrome that shares symp-
toms and laboratory characteristics with idiopathic SLE
[2]. More than 80 drugs have been associated with DILE
[2]. Paclitaxel is an anti-cancer agent that is used for the
treatment of patients with breast cancer, ovarian cancer,
gastrointestinal cancers and tumors of the head and
neck. Paclitaxel treatment is often associated with neu-
rological pain, hair loss and nail changes, but skin disor-
ders such as photosensitivity are less common.
Paclitaxel has been associated with inducing acral
erythema [3], scleroderma [4] and Stevens-Johnson
syndrome [5]. A recent case report also described pacli-
taxel-induced cutaneous lupus erythematosus in patients
with Sjögren’s syndrome [6].
Bevacizumab is an anti-vascular endothelial growth
factor (anti-VEGF) antibody that may improve the effect
of taxane-based regimens in the treatment of metastatic
breast cancer [7]. A recent study has shown that bevaci-
zumab-paclitaxel combination therapy prolongs progres-
sion-free survival, compared with paclitaxel alone, in
patients with metastatic breast cancer [8]. The most
common toxicities associated with bevacizumab are
hypertension and hemorrhage, gastrointestinal perfora-
tion, arterial thromboembolism, impaired wound healing
and proteinuria [9]. Cutaneous disorders are rare side
effects of bevacizumab therapy. Cutaneous side effects
were not mentioned at all in an earlier study in which
365 patients were treated with bevacizumab-paclitaxel
combination therapy, and the overall frequency of grade
3 allergic reactions in that study was only 3% [8]. In the
present case report, we describe a patient without
known previous autoimmune disorders who developed a
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sus (LE) after therapy with paclitaxel and bevacizumab.
Case presentation
Our patient was a 58-year-old Caucasian woman who
had been diagnosed in September 1999 with estrogen
receptor-positive (ER
+), progesterone receptor-positive
(PR
+), human epidermal growth factor receptor 2/neu
(Her2/neu)-negative ductal breast cancer assessed as
American Joint Committee on Cancer stage IIA (pT1
pN1 M0 G1). She was initially treated with partial mas-
tectomy and evacuation of axilla. No signs of dissemi-
nated disease were detected. Radiotherapy (50 Gy) was
given to the left breast and lymph nodes. The patient
received adjuvant tamoxifen therapy (20 mg/day) for five
years, until January 2005. In 2003, she was diagnosed
with hypothyroidism and treated with thyroxin substitu-
tion daily. In 2004, she was diagnosed with high blood
pressure and was treated with metoprolol (47.5 mg/day).
In March 2007, routine mammography showed a new
local tumor in the left breast, and radical mastectomy
was performed. The ductal residual tumor was assessed
as pT1 pNX G2 and was ER
+,P R
+ and Her2/neu-nega-
tive. A palpable tumor was found at the left side of her
neck, and a fine-needle biopsy showed metastasis of her
breast cancer. A whole-body computed tomographic
scan showed multiple liver metastases and multiple
metastases in the left lung and the spleen.
First-line chemotherapy was started with weekly pacli-
taxel 80 mg/m
2 on days 1, 8 and 15 of a 28-day cycle
and concomitant bevacizumab 10 mg/kg every two
weeks. Her blood pressure was elevated after the first
infusion, and the previous metoprolol dose was doubled
to 90 mg/day. Her serum creatinine and bilirubin levels
were normal (creatinine 77 μmol/L, normal range 50 to
90 μmol/L; bilirubin 18 μmol/L, normal range 5 to 25
μmol/L) before beginning therapy. Her serum alkaline
phosphatase level was increased (214 U/L, normal range
35 to 105 U/L). After two combined infusions of pacli-
taxel-bevacizumab, an itchy papulosquamous rash was
apparent on sun-exposed areas of the skin of her arms,
legs and face (Figure 1). The rash was treated with cetir-
izine (10 mg/day) and topical corticosteroids. Her blood
pressure was further elevated, and metoprolol was
replaced by candesartan cilexetil-hydrochlorothiazide
combination therapy. Her paclitaxel-bevacizumab treat-
ment continued, but the rash on her arms and legs wor-
sened. The patient was referred to a dermatologist, and
skin biopsies were performed. The skin biopsy specimen
showed non-specific inter-phase dermatitis, which may
be associated with LE (see Figure 2). A direct immuno-
fluorescence study did not show deposition of immuno-
globulins at the basement membrane zone, but C3 on
Civatte bodies was positive. Simultaneously, her serum
anti-SSA/Ro (> 240 U/mL, normal range 0 to 6.99 U/
mL), anti-SSB/Ro (94.4 U/mL, normal range 0 to 6.99
U/mL) and anti-extractable nuclear antigen (anti-ENA)
antibodies were positive. Paclitaxel-bevacizumab combi-
nation therapy was discontinued and replaced by cyclo-
phosphamide, epirubicin, fluorouracil (CEF), after which
her skin rash disappeared within two weeks. Her serum
anti-SSA/Ro antibodies were 8.1 U/mL and her anti-
SSB/Ro antibodies were 5.0 U/mL when checked three
months after discontinuation of the therapy. Her serum
anti-ENA antibodies were not checked. Her serum alka-
line phosphatase level had decreased during therapy
(from 274 U/L at maximum to 121 U/L, normal range
35 to 105 U/L), and her other liver enzyme values were
not markedly changed.
Discussion
Common presenting symptoms of DILE include arthral-
gia, myalgia, malaise and fever [2]. The laboratory pro-
file of DILE includes anti-histone antibodies, especially
immunoglobulin G anti-DNA antibody, in the absence
of other anti-nuclear antibody specificities [2]. Typically,
the symptoms improve within days or weeks after dis-
continuation of the suspected drug. DILE with cuta-
neous manifestations has rarely been described in
patients treated with paclitaxel [6] or docetaxel [10]. In
earlier studies, taxane-related cutaneous LE has been
related to a pre-existing history of Sjögren’ss y n d r o m e
[6]. Our patient had no history of autoimmune disor-
ders; however, hypothyroidism was present. This might
be associated with the previous adjuvant radiotherapy
for local breast cancer.
Skin acneiform rash is a typical side effect of cetuxi-
mab but has seldom been described in association with
bevacizumab. However, Gotlib and co-workers [11]
described a patient with colorectal cancer who devel-
oped a skin rash secondary to bevacizumab therapy that
correlated with response. In our patient, cutaneous toxi-
city was apparent only in sun-exposed areas, that is, the
f a c e ,f o r e a r m sa n dl e g s ,i nc o n t r a s tt ot h em o r ec o m -
monly seen acneiform rash on the face, neck and upper
back of patients treated with cetuximab [12].
In our case, the cutaneous biopsy showed inter-phase
dermatitis (Figure 2), which is a non-specific cutaneous
reaction to several stimuli. It is seen in lichen planus,
other lichenoid reactions, erythema multiforme and LE,
all of which can be caused by drugs. Typical lichen pla-
nus can be ruled out morphologically and clinically. The
histological pattern matches that of erythema multi-
forme or subacute LE. Positive anti-SSA/Ro antibodies
support the latter possibility. However, direct immuno-
fluorescence with positive C3 in the dermoepithelial
junction was non-specific and the typical lupus band
was not observed.
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patients treated with bevacizumab. However, previous
studies involving skin specimens have shown that recep-
tors for VEGF are present in keratinocytes in human
epidermis [13]. Similarly, Kikuchi and co-workers [14]
have shown that serum concentrations of VEGF are
increased in collagenous diseases, suggesting that this
growth factor might also be important in the pathogen-
esis of collagenous diseases other than rheumatoid
arthritis. In our case, it is probable that the cutaneous
Figure 1 Patient’s forearm on day 36 after beginning paclitaxel-bevacizumab combination therapy.
Figure 2 Inter-phase dermatitis in skin biopsy taken from the patient’s forearm. Basal degeneration as well as some regeneration is seen
in epidermal keratinocytes. An apoptotic dyskeratotic cell is present in the horn layer. A slight lymphocytic reaction and some melanophages
were found in the papillary dermis. An occasional lymphocyte was seen in the epidermis (hematoxylin and eosin stain; original magnification, ×
250).
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role of bevacizumab cannot be ruled out. We suggest
that this skin reaction was specifically related to these
drugs because it did not reappear when the patient
received CEF treatment, even though fluorouracil is
known to be a photosensitizing agent which can also
induce DILE [2].
Conclusions
We conclude that paclitaxel-bevacizumab combination
treatment might cause cutaneous LE in patients with no
history of autoimmune disorders. In addition, while the
use of bevacizumab for various indications such as
metastatic renal cancer, colorectal cancer, lung cancer
and breast cancer is increasing, rare side effects such as
skin disorders are possible.
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